Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment

Immunobiology

Volumn 207, Issue 3, 2003, Pages 161-168

  Bíró, Adrienn ^a   Horváth, Anna ^a   Varga, Lilian ^b   Nemesánszky, Elemér ^c   Csepregi, Antal ^c   Dávid, Károly ^d   Tolvaj, Gyula ^d   Ibrányi, Endre ^e   Telegdy, László ^e   Pár, Alajos ^f   Romics, László ^a,g   Karádi, István ^a,g   Horányi, Margit ^b   Gervain, Judit ^h   Ribiczey, Pál ⁱ   Csöndes, Mihály ^j   Füst, George ^a,g  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b NATIONAL MEDICAL CENTER   (Hungary)

^c St John of God in Budapest ^*  (Hungary)

^d 1st Department of Medicine Central Hospital Ministry of the Interior   (Hungary)

^e Szent Laszlo Hospital   (Hungary)

^f UNIVERSITY OF PÉCS   (Hungary)

^g INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^h St George's Hospital   (Hungary)

ⁱ County Hospital ^*  (Hungary)

^j Petz Hospital   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIBODY; ANTIRETROVIRUS AGENT; CHOLESTEROL; CHOLESTEROL ANTIBODY; COMPLEMENT COMPONENT C5B; INTERLEUKIN 6; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS LOAD;

EID: 0037514556     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00229     Document Type: Article

References (28)

1. Alving CR and Swartz GM Jr. 1991. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Immunology. 10: 441-453.
2. Alving CR and Wassef M. 1999. Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunol. Today. 20: 362-366.
3. Alving CR, Swartz GM Jr and Wassef M. 1989. Naturally occurring autoantibodies to cholesterol in humans. Bichem. Soc. Trans. 629: 637-639.
4. Bíró L, Varga L, Pár A, Nemesánszky E, Telegdy L, Ibrányi E, Dávid K, Horváth G, Szentgyörgi L, Nagy I, Dalmi L, Abonyi M, Füst G, Horányi M and Csepregi A. 2000a. C5b-9 and interleukin-6 in chronic hepatitis C. Scand. J. Gastroenterol. 10: 1092-1096.
5. Bíró L, Varga L, Pár A, Nemesánszky E, Csepregi A, Telegdy L, Ibrányi E, Dávid K, Horváth G, Szentgyörgi L, Nagy I, Dalmi L, Abonyi M, Füst G and Horányi M. 2000b. Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b. Immunol. Lett. 72: 69-74.
6. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G and Piette JC. 2000. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine. 79: 47-56.
7. Deppisch R, Schmitt V, Bommer J, Hansch GM, Ritz E and Rauterberg EW 1990. Fluid phase generation of terminal complement complex as a novel index of biocompatibility. Kidney Int. 37: 696-706.
8. Di Bisceglie AM. 1999. Hepatitis C - Virology and future antiviral targets. Am. J. Med. 107: 45S-48S.
9. Dijkstra J, Swartz GM, Raney JJ, Aniagolu J, Toro L, Nacy CA and Green SJ. 1996. Interactions of anti-cholesterol antibodies with human lipoproteins. J. Immunol. 157: 2006-2013.
10. Fabris C, Federico E, Soardo G, Falleti E and Pirisi M. 1997. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin. Chim. Acta 261: 159-165.
11. Favre D, Berthillon P and Trépo C. 2001. Removal of cell-bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro. C R Acad. Sci. III 324: 1141-1148.
12. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P and Grunfeld C. 1993. The hypertrigliceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metabol. 76: 1423-1427.
13. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J and Pierson RN. 1989. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86: 27-31.
14. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P and Feingold KR. 1992. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency syndrome. J. Clin. Endocrinol. Metabol. 74: 1045-1052.
15. Horváth A, Bánhegyi D, Biro A, Ujhelyi E, Veres A, Horváth L, Prohászka Z, Bácsi A, Tarján V, Romics L, Horváth I, Tóth FD, Füst G and Karádi I. 2001a. High level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. Immunobiol. 203: 756-768.
16. Horváth A, Füst G, Horváth I, Vallus G, Duba J, Harcos P, Prohászka Z, Rajnnavolgyi E, Janoskuti L, Kovacs M, Csaszar A, Romics L and Karádi I. 2001b. Antibodies against cholesterol (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis. 156: 185-192.
17. Jarvis LM, Ludlam CA, Ellender JA, Nemes L, Field SP, Song E, Chuansumrit A, Preston FE and Simmonds P. 1996. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood. 87: 3007-3011.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW and Wollman J. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1: 431-435.
19. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia and Ideo G. 1996. Serum cholesterol and hepatitis C. Ital. J. Gastroenterol. 28: 436-440.
20. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R et al. Geographical distribution of hepatitis C virus genotypes in blood donors? An international collaborative survey. J. Clin. Microbiol. 32: 884-892.
21. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S and Thomssen R. 1999. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57: 223-229.
22. Nguyen DH and Hildreth JEK. 2000. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74: 3264-3272.
23. Pirich C, Efthimiou Y, O'Grady J, Zielinski C and Sinzinger H. 1996. Apoliporotein A and biological half-life of prostaglandin I2 in HIV-1 infection. Thromb. Res. 81: 213-218.
24. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilléres O and Poupon R. 2001. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 34: 428-434.
25. Soardo G, Pirisi M, Fonda M, Fabris C, Falleti E, Toniutto P, Vitulli D, Cattin L, Gonano F and Bartoli E. Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J. Interferon Cytokine Res. 15: 705-712.
26. Szebeni J, Baranyi B, Savay S, Bodo M, Morse DS, Basta M, Stahl GL, Bunger R and Alving CR. 2000. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 279: H1319-H1328.
27. Thomssen R, Bonk S, Propfe C, Heerman KH, Kochel HG and Uy A. 1992. Association of hepatitis C virus in human sera with beta lipoprotein. Med. Microbiol. Immunol. 181: 293-300.
28. Thomssen R, Bonk S and Thiele A. 1993. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. 182: 329-334.